Skip to content

Bausch + Lomb BLCO Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

AbbVie logo
AbbVieABBV
Viatris logo
ViatrisVTRS
Baxter International logo
Baxter InternationalBAX
Kenvue logo
KenvueKVUE
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.3B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's indefinite- lived intangible impairment?
Bausch + Lomb (BLCO) reported indefinite- lived intangible impairment of $7.37B in Q1 2026.
How has Bausch + Lomb's indefinite- lived intangible impairment changed year-over-year?
Bausch + Lomb's indefinite- lived intangible impairment decreased by 0.1% year-over-year, from $7.38B to $7.37B.
What is the long-term trend for Bausch + Lomb's indefinite- lived intangible impairment?
Over 4 years (2021 to 2025), Bausch + Lomb's indefinite- lived intangible impairment has grown at a 8.2% compound annual growth rate (CAGR), from $5.42B to $7.43B.